inclus back lab network larg
anticip investor believ agreement sign modestli
better expect inclus value-bas incent plan
design enhanc could boost econom contract drive
increment ep growth lt term market share ramp see gain
volum quickli fl state like see gradual share
contract award larg expect posit nonetheless
boost revenu ep growth albeit still within management lt guidanc rang
announc re-inclus lab network begin
larg expect investor topic discuss length
lh even previous note contract win would alter lt revenue
ep growth guidanc said view announc still notabl posit
could boost ep
contract detail provid suggest slightli better arrang
investor expect contract win surpris
believ investor expect tradit commod type contract agreement
announc last night includ value-bas incent could actual boost
econom embed street expect addit management commentari
suggest cost need ramp contract alreadi embed
guidanc assumpt posit unexpect data point
expect market share gain ramp gradual except fl healthcar
provid accustom refer patient lab test lh
region provid believ market physician outreach process
undertak order gain share lab referr said believ
retail strategi locat psc safeway store tool use acceler share
gain market ampl geograph concentr one area see
quickli gain share fl alreadi strong foothold given exist prefer
relationship florida
maintain hold valuat rais pt reflect posit ep
growth adjust pt deriv appli lt price-to-earnings delta vs risk
began report adj ep exclud amort expens
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
hold rate larg due valuat well
risk ep growth pressur result pama
although give credit continu deliv
stabl revenu earn perform time
provid see challeng pama litig
success activ spend ratchet
contract award larg expect posit
nonetheless boost revenu ep growth albeit
management shown progress deliv consist
posit organ growth demonstr abil re-
acceler ep growth ep pressur pama
could bring well dgx valuat keep us hold
abl continu grow volum
rang extract effici via invigor
expect deploy toward share
buyback dividend
supplement top line growth acquisit
hospit independ lab believ
gener signific free cash flow could
pama litig success reimburs chang
result less expect medicar revenu cut
ep valuat premium
organ volum declin isnt abl
supplement a-support growth
revenu per requisit may continu
pressur due medicar pama commerci
pama litig unsuccess reimburs cut
expect
ep valuat price-to-earnings low
end histor rang price target
page
pleas see import disclosur inform page report
